Transcript Highlights:

• strike-everything amendment that prohibits access from establishing more restrictive utilization controls for FDA-approved
• strike-everything amendment that prohibits access from establishing more restrictive utilization controls for FDA-approved

Summary: The meeting covered seven Senate-amended House bills on the caucus agenda. HB 248 was described as changing prior language about private process servers and, in the Senate strike-everything version, prohibiting more restrictive utilization controls for FDA-approved non-opioid pain medications than those applied to opioid or narcotic drugs, with a repeal date of September 1, 2028. HB 2265 would continue limiting certain court fees charged to criminal defendants, though the Senate removed the provision barring courts from creating new fees without express legislative authorization. HB 2404 would require authorized transporters for certain mental health transports; the sponsor explained the Senate changes delay implementation until 2030 and preserve officer involvement when safety concerns exist. HB 2611 would strengthen DCS group foster home safety rules, including drug screening consequences for employees and additional security standards, with the sponsor emphasizing child safety and accountability. HB 2950 would authorize tourism improvement areas and lodging assessments, with the Senate shifting assessment approval to the governing body and removing some new-business assessment requirements. HB 2986 made multiple ADEQ-related changes, including replacing the recycling fund with the solid waste fee fund and expanding its uses. HB 2995 revised child custody and domestic violence standards to make domestic violence a dominant factor in custody decisions, with Senate amendments adjusting findings, evidence standards, burdens of proof, and adding an emergency clause. Most bills were met with sponsor concurrence and no recorded opposition. HB 2404 drew questions about whether peace officers would still be involved in transports; the sponsor clarified officers would still handle the initial pickup and could be recalled if the person remained high risk or aggressive. HB 2611 was supported as a child-protection measure based partly on recommendations from youth in group homes. HB 2950 was described as a private, opt-in tourism financing tool that would cost taxpayers nothing. HB 2986 was noted as having passed the Senate unanimously. HB 2995 generated the most discussion. Supporters said it addresses coercive control and financial abuse in domestic violence cases and was developed through a lengthy stakeholder process, including court input, to better protect children and families. One member objected that the bill’s wording could sweep in ordinary marital conduct, such as managing finances, making demeaning remarks, or threatening to call police or file for divorce, and urged an amendment to narrow the language. Supporters responded that the bill is aimed at coercive control in custody disputes, that the emergency clause reflects immediate need, and that fixes could be revisited later. The caucus ended with a reminder about a second caucus after floor for the budget bill.

Transcript Highlights:

• And they all have to be okayed by FDA or USDA or food and drug.
• Yeah, that's FDA or FIFA or whatnot.
• <01:22:05.679> Yeah, FDA or USDA or food and drug. Yeah, FDA or USDA or food and drug.
• <01:22:08.080> So,<01:22:09.040> we that's FDA or FIFA or whatnot.
• So, we that's FDA or FIFA or whatnot.

Keywords: 926, house, all

Summary: The House opened with a devotional for Mental Health Awareness Month, focused on the fragility and renewability of mental health and the importance of human connection, kindness, and reaching out to people who are struggling. The chamber then handled several referral items, including first reading and referral of Senate Bill 329, an act relating to criminal procedures involving firearms, to the Judiciary Committee. It also referred Senate Bills 323 and 326 to the Committee on Appropriations because they carry appropriations, and noted that Senate Bill 278, relating to cannabis and state revenue, had been reported favorably with amendment and was referred to Ways and Means under House Rule 35A. The House took up Joint Senate Resolution 53 on weekend adjournment for May 15, 2026, and adopted it in concurrence by voice vote. The chamber also read House Concurrent Resolution 284 honoring former Senate Majority Leader and Department of State’s Attorneys and Sheriffs’ Executive Director John F. Campbell for his public service, including his work on marriage equality and gun control, and members gave remarks recognizing his leadership, humor, and impact on the institution. Several guests were welcomed and recognized during announcements, including a representative involved in a diaper drive, local officials, and Norma Malone, who was honored for decades of public service in Barry Town and related local boards. The main floor action was on Proposal 4, a proposed constitutional amendment on equality of rights. The Judiciary Committee recommended concurrence, and the member from Burlington explained the amendment’s purpose and process, emphasizing that it would add an equal protection guarantee to the Vermont Constitution covering race, ethnicity, sex, religion, disability, sexual orientation, gender identity, gender expression, and national origin, while preserving other constitutional protections. The member also reviewed the proposal’s prior passage in both chambers in the previous biennium and its current path toward appearing on the November 2026 ballot if approved again by the House and Senate. The transcript ends while the House is still hearing extended remarks on Proposal 4, with no final vote on the amendment shown in the excerpt.

Transcript Highlights:

• So, we want to make sure that access to all FDA-approved sunscreens is kept available and that state
• funds should be made for all FDA-approved, you know, quote-unquote legal sunscreens for Hawaii should
• So, we want to make sure that access to all FDA-approved sunscreens is kept available and that state
• funds should be made for all FDA-approved, you know, quote-unquote legal sunscreens for Hawaii should
• >> Yeah, and then under FDA approval is... >> So, specifically, you believe these products pose less

Bills: SB2489, SB2310, SB2372, SB2426, SB2334, SB2925, SB3323

Keywords: invasive species, agriculture, biosecurity, lease provisions, environment, natural resources, flood management, vegetation removal, Kainahola stream, Hawaii legislation, trees, exceptional trees, significant trees, urban forestry, arborist advisory committee, DLNR, Department of Land and Natural Resources, University of Hawaii, county planning, tree preservation

Summary: The committee heard several measures related to agriculture, invasive species control, trees, reef protection, and land use. SP 2489 would require Department of Agriculture and Biosecurity leases to include access, invasive-species control, and termination provisions; DAB and DLNR supported it, as did several outside groups, while the Hawaii Farm Bureau and Hawaii Cattlemen’s Council raised concerns about notice, cooperation with lessees, and placing penalties on leaseholders for preexisting infestations. The chair noted six testifiers in support, one opposed, and three with comments. SP 2310 would appropriate funds to remove overgrown vegetation from the Kohola stream. DAB supported the bill but explained that the work already completed by its contractor stopped at a DOT boundary, and that the affected parcel appears to be a DOT highway segment on ceded lands; the committee discussed whether the appropriation should instead go to DOT. SP 2372, on exceptional and significant trees, received support from DNR and Outdoor Circle, with testimony describing trees as critical infrastructure and suggesting technical amendments to committee membership and the process for recommending trees to county councils. SP 2426, which would authorize DNR to contract with private parties to maintain sunscreen dispensers at state beaches and promote mineral-based sunscreen as reef-protective, drew support from DNR and reef advocates, while another witness questioned the science behind claims about mineral versus chemical sunscreens and urged broader environmental solutions. SP 2334 would impose a land conversion fee on agricultural land converted to other uses, create a fee fund for programs including healthy soils, and require state agricultural lands to use a conservation metric. DAB offered comments, and testimony from climate and farm groups generally supported the conservation goals but questioned references to programs not yet in place and objected to language excluding solar and wind uses, with one witness urging that agri-voltaics remain allowed. SP 2925, concerning coconut trees, would recognize them as food, water, and cultural resources, require signage for landscape palms, set labeling standards, and create a tax credit for naturally managed consumable coconut trees. DAB shifted from opposition to comments, DNR supported, and testimony from cultural and subsistence advocates strongly backed the bill as a response to coconut rhinoceros beetle impacts; committee questions focused on enforcement of signage, inspection resources, and the proposed tax credit.

Transcript Highlights:

• bill will allow public schools to purchase, use, and maintain emergency opioid antagonists that are FDA
• Now, it's also NAL-FEN-Mephine, and as we know, FDA is also looking at all the medications that are in

Summary: The Human Services Subcommittee considered three bills and reported all of them favorably by unanimous votes. HB 355, by Rep. Jay Alvarez, would allow public K-12 schools and postsecondary institutions to purchase, use, and maintain FDA-approved emergency opioid antagonists rather than being limited to naloxone. The bill was described as giving schools more flexibility and a lower-cost option for overdose response; it received supportive public testimony and passed 18-0. HB 531, by Rep. Hanchowski, expands background screening requirements for child care facilities and programs to include certain recreational enrichment programs, and creates a statewide public awareness campaign about screening requirements. An amendment narrowed the definition of recreational enrichment programs to in-person dance, gymnastics, and martial arts lessons and conformed a statutory cross-reference; the amendment was adopted without objection. The bill then passed 18-0, with support from Florida Smart Justice Alliance and some discussion about strengthening enforcement against bad actors. HB 1127, by Rep. Weinberger, addresses child welfare by creating a treatment foster care pilot program for high-acuity children, directing DCF to study residential treatment capacity, and improving data collection on commercially sexually exploited children. The bill also includes recruitment and funding proposals for foster parents and workforce strategies for DCF. Members praised the bill’s focus on difficult cases and system gaps, public testimony was supportive, and the bill passed 18-0. The meeting then adjourned.

Transcript Highlights:

• Now, there are several FDA-approved medications for opioid use disorder, which function...
• Now, there are several FDA-approved medications for opioid use disorder, which function by alleviating
• So that's FDA, the IRS, the U.S. Attorney's Office.
• But according to a 2025 FDA report, 7-OH produces respiratory depression at a rate three times that of
• The sale of a new drug without FDA approval and the rigorous safety testing required for such approval

Keywords: 959, house, all

Transcript Highlights:

• Federally, the FDA has assigned its breakthrough therapy designation to multiple psychedelics.
• Some such introductions have recently been made with FDA-approved medications, such as radanolone, which
• approval by some are called psychedelics and not by others; they already have FDA approval.
• approval by some are called psychedelics and not by others, they already have FDA approval.
• Senator Talents, is psilocybin approved by the FDA? No, it is a Schedule I. Thank you.

Keywords: 995, all

Summary: The Joint Committee on Mental Health, Substance Use and Recovery opened its first public hearing of the 2025–26 session with remarks from the Senate and House chairs outlining the committee’s priorities. They noted recent work on addiction and recovery legislation, the ongoing youth behavioral health crisis, and that members might need to leave periodically for floor votes. The chairs explained hearing procedures, including three-minute testimony limits, written testimony deadlines, and reporting deadlines for Senate and House bills. The hearing then focused on several bills related to youth mental health, overdose prevention, and psychedelic treatment research. A major portion of the hearing centered on bills to improve youth crisis response and overdose prevention. Testimony strongly supported bills to print the 988 Suicide and Crisis Lifeline on student ID cards, with speakers from mental health organizations, crisis centers, and individuals sharing personal stories of depression, suicide attempts, and the importance of making 988 as familiar as 911. Another set of bills would require schools to stock naloxone and provide overdose prevention education. Physicians, harm reduction advocates, students, and grieving family members testified that school-based Narcan access and education could save lives, reduce stigma, and help students recognize overdoses and understand Good Samaritan protections. Senator O’Connor and Tamika Perry also testified for a bill to strengthen substance use prevention education and reduce overdose abandonment, emphasizing the need to teach students about overdose risks and the legal protections for calling 911. The committee also heard testimony on a bill to authorize a pilot program for psychedelic treatment in licensed facilities. Senator Friedman and several medical and behavioral health professionals argued the proposal was a narrow, research-based approach distinct from the broader ballot question rejected in 2024. They said the bill would allow only a small number of supervised clinics to use psychedelics for conditions such as depression, PTSD, anxiety, and substance use disorders, with data reporting and Department of Public Health oversight. Supporters described it as a cautious way to study promising treatments while avoiding unsupervised or commercialized use. Finally, the committee heard support for a bill to create a special commission and five-year strategic plan for children’s behavioral health services, with testimony that the current system is fragmented, difficult for families to navigate, and strained by workforce and funding challenges. No votes or final actions were taken during the hearing; the committee primarily received testimony and questions on the bills.

Transcript Highlights:

• The FDA trusts lay people to do them. They are digital tests.
• Any other FDA-approved opioid antagonist, including an expired opioid antagonist, to treat a drug overdose
• , I'm just going to say Narcan for now, Narcan out there that has officially label expired, but the FDA
• FDA all agree: expired Narcan is better than no Narcan. Thank you very much for the time.
• FDA all agree, expired NARCAN is better than no NARCAN. Thank you very much for the time.

Keywords: 1182, all

Summary: The committee heard House Bill 2433, which would require insurers offering Medicare supplement policies to people 65 and older to also offer them to Medicare beneficiaries under 65 with ALS or end-stage renal disease, with enrollment periods and premium protections tied to 65-year-old rates. Supporters, including dialysis and ALS advocates, said the bill would help a small population facing high out-of-pocket costs and could improve access to transplants and care; opponents argued it would shift costs onto older seniors and raise Medigap premiums. The committee recommended the bill do pass on a 12-0 vote. The committee also heard House Bill 2593, appropriating $1.5 million to the University of Arizona for the Arizona Perinatal Psychiatry Access Line. The sponsor and physicians testified that the line helps obstetric and pediatric providers quickly consult on perinatal depression, postpartum psychosis, suicidality, and other mental health crises, improving outcomes for mothers, children, and families and reducing costly emergency and crisis care. The bill received a do pass recommendation on a 10-1 vote. House Concurrent Resolution 2013, proclaiming June 2026 as Celebrate Life Month, drew emotional testimony from a young woman with spina bifida and another speaker supporting the sanctity of life. Some members objected that the state should focus on practical supports such as paid leave, child care, and health care access, while others supported the resolution as a statement of human dignity. The resolution passed the committee 7-5. The committee then approved House Bill 4010, creating a Board of Genetic Counselors and licensure standards, after testimony from genetic counselors and a patient advocate about the need for qualified counseling and better access; it passed 11-1. Later, the committee approved House Bill 2196, which would require pharmacy benefit managers to reimburse non-affiliated pharmacies at least their acquisition cost and pay a dispensing fee, and establish an appeals process. Independent pharmacists and their coalition said PBM practices are driving closures and unfairly favor affiliated pharmacies, while PBM and employer representatives warned of major cost increases and said the bill would interfere with private contracts; the bill passed 11-1. The committee also adopted a strike-everything amendment to House Bill 2182 requiring insurers and health plans to report claims denial and prior authorization data to DIFI, and then gave the amended bill a 12-0 do pass recommendation. Finally, the committee approved House Bill 2189, directing the Board of Nursing to update rules for licensed health aides and collect annual data, with the sponsor and board staff saying it would help implement routine ventilator care in the home; it passed 12-0. The committee then began hearing House Bill 2404, a strike-everything amendment on inter-facility transports for behavioral health patients, but the transcript cuts off before action on that bill.

Transcript Highlights:

• Well, I mean, it could be FDA, it could be USDA, it could be, it's not unusual.
• now in trying to help us, you know. have healthy food and so you know it could be something from the FDA
• I would assume that if it comes out of the FDA that the secretary of that agency is going to know what's
• Are you aware that the FDA has oversight over certain other food and safety labeling standards, but this
• What does the FDA do? Those guidelines have been out for decades.

Bills: SB835, SB3070, SB22, SJR59, SB926, SB1494, SB251, SB456, SB500, SB1307, SB2615, SB2995, SB2321, SB973, SB974, SB865, SB506, SB781, SB1522, SB1558, SB510, SB667, SB763, SB2073, SB1858, SB1660, SB505, SB2900, SB1433, SB1540, SB1964, SB1300, SB1644, SB2217, SB2373, SB2431, SB1758, SB2480, SB3039, SB3047, SB3073, SB2920, SB2781, SB826, SB766, SB2460, SB527, SB1946, SB2885, SB1243, SB2610, SB2595, SB857, SB37, SB8, SB10, SB227, SB261, SB12, SB15, SJR27, SB552, SB835, SB3070, SB22, SJR59, SB25, SB57, SB127, SB293, SB441, SB3059, SB512, SB241, SB1718, SB140, SB2055, SB2075, SB2018, SB1534, SB1567, SB785, SB1233, SB1580, SB1663, SB413, SB447, SB519, SB467, SB1579, SB1191, SB1021, SB1838, SB2807, SB2835, SB546, SB2121, SB2167, SB2035, SB2024, SB1032, SB1049, SB1266, SB1400, SB1302, SB401, SB1596, SB1281, SB1242, SB1343, SB310, SB1346, SB2753, SB2703, SB2221, SB1719, SB2177, SB800, SB790, SB748, SB571, SB1957, SB1923, SB1896, SB1760, SB1335, SB2368, SB2477, SB2587, SB2972, SB2986, SB2965, SB1563, SB1467, SB1164, SB1137, SB614, SB705, SB961, SB918, SB955, SB869, SB850, SB863, SB1610, SB1055, SB2206, SB457, SB2337, SB1362, SB926, SB1494, SB251, SB456, SB500, SB1307, SB2615, SB2995, SB2321, SB973, SB974, SB865, SB506, SB781, SB1522, SB1558, SB510, SB667, SB763, SB2073, SB1858, SB1660, SB505, SB2900, SB1433, SB1540, SB1964, SB1300, SB1644, SB2217, SB2373, SB2431, SB1758, SB2480, SB3039, SB3047, SB3073, SB2920, SB2781, SB826, SB766, SB2460, SB527, SB1946, SB2885, SB1243, SB2610, SB2595, SB857, SCR9, HB5560, HB762, HB 107, HB 114, HB300, HB138, HB4386, HB2495, HB581, HB3348, HB5323

Keywords: sexual abuse, nondisclosure agreements, confidentiality agreements, public policy, victim rights, lottery, bingo, regulation, Texas Lottery Commission, Department of Licensing and Regulation, criminal offenses, state administration, audits, transfers, Texas, moving image industry, incentive program, film production, grant funding, job creation

Transcript Highlights:

• They are medical procedures using FDA-regulated products with significant risks and benefits.
• The FDA has also warned about delayed inflammatory reactions that can occur after illnesses, vaccinations
• Nodules have been reported with filler injections, and in 2023 the FDA updated the guidance to reflect
• Additionally, in 2023, the FDA updated its dermal fillers guidance to report delayed-onset inflammation
• They use FDA-regulated devices that can alter or damage the skin and the subcutaneous tissue.

Keywords: 995, all

Summary: The committee opened a hearing of the Joint Committee on Consumer Protection and Professional Licensure focused on health care and human services, reviewed testimony logistics, and then heard a long series of witnesses on several bills. Much of the testimony centered on interstate licensure compacts for dentistry, social work, and occupational therapy, with supporters arguing these compacts would improve workforce mobility, continuity of care, and access while preserving state oversight and public protection. Dental witnesses were split on H.455/S.257, with supporters backing the AADB dental compact for its hands-on exam, background checks, and disciplinary safeguards, while opponents argued a competing compact would better promote portability and avoid conflicts tied to proprietary testing and outside commissions. Social work witnesses strongly supported H.380/S.252, emphasizing continuity of care for clients who move across state lines, reduced costs and delays for practitioners, and the compact’s public-protection features; occupational therapy witnesses similarly supported H.427/S.256, citing access, telehealth, military families, and maintained standards. The committee also heard testimony on S.242, which would expand licensure for lactation care providers. Supporters, including lactation counselors and health center staff, said adding certified lactation counselors and related credentials would expand access, improve breastfeeding support, and allow reimbursement for services now often provided without billing. They described the training required and said the bill would help families, especially in underserved communities. Representative James O’Day also testified in support of the social work compact, and a Council of State Governments witness provided background on compact mechanics and state participation. Another major topic was H.419/S.214 on medical debt. Physicians and researchers testified that cancer patients experience long-lasting medical debt and collections burdens, and they supported limits on the sale and collection of medical debt, bans on reporting it to credit bureaus, and related consumer protections. The hearing also included H.465 on a pathway to special licensure for certain long-term limited-registration dentists serving MassHealth patients, which Representative Senna supported as a way to allow immigrant dentists to practice independently. Finally, the committee heard sharply divided testimony on H.444/S.284, which would allow trained dental hygienists to administer Botox and dermal fillers: supporters framed it as a safe, preventive, and access-expanding tool for TMJ, bruxism, and pain management, while dermatologists opposed it as outside hygienists’ training and a patient-safety risk. No votes or formal actions were taken during the hearing.

Transcript Highlights:

• They just got their FDA clearance.
• They just got their FDA clearance.
• They just got their FDA clearance.
• They just got their FDA clearance.

Keywords: 994, senate, all

Summary: The Senate opened with prayer, the Pledge of Allegiance, journal approval, and numerous guest introductions, including students, community leaders, food bank representatives, and visitors connected to Hunger Free West Virginia Day. A resolution recognizing March 10, 2026, as Hunger Free West Virginia Day was adopted, and Senate Concurrent Resolution 7 on the Southern West Virginia water crisis was referred to the Rules Committee. The chamber also heard remarks highlighting Hunger Free West Virginia’s work and a West Virginia company, Unigen, developing pharmaceutical manufacturing in the state. The Senate concurred with House amendments and passed several measures, including Senate Bill 467 on enforcement of Purple Heart parking spaces, Senate Bill 712 on cattle guards on certain public roads, and Senate Bill 781, a supplemental appropriation measure that was also made effective from passage. The chamber then adopted and passed Senate Bill 844, a large supplemental appropriation to the Department of Human Services, and Senate Bill 87, a supplemental appropriation to the Department of Commerce, both effective from passage. Other third-reading bills passed included the Blue Envelope Program for drivers with autism, dementia, or intellectual and developmental disabilities; coverage for scalp cooling systems during chemotherapy; expansion of sex-offender registration to include solicitation of a minor and non-consensual disclosure of private images; child safety reporting requirements for school personnel; age-verification requirements for websites hosting harmful sexual material; free Gold Star parent vehicle registration; online training and updated standards for sanitarians; sheriff hiring authority; organ donor registration through voter registration; a Cold Case Task Force; abandoned vehicle title procedures; nutrition continuing education for physicians; special plate rules; gift card fraud offenses; protections for athletic officials; in-year school personnel movement; administrative services powers; pharmacy benefit manager regulation; vape shop regulation; reduced parole supervision fees; disability service credit for certain troopers; property valuation reporting changes; and quarterly Hope Scholarship payments. The Senate also advanced a large number of House bills and committee substitutes on second reading, including supplemental appropriations and measures on mental health examinations, dog registration rules, juvenile jurisdiction on military installations, military interpersonal violence, kinship care subsidies, a statewide prevention plan, contraband smuggling into federal prisons, forestry equipment levy treatment, and Commerce Department rules for microgrid districts and high-impact data centers. Several committee amendments were adopted, and many bills were advanced to third reading without objection. No executive communications were reported.

Transcript Highlights:

• may have. have rare medical conditions like myself, and have life-threatening reactions. to the only FDA-approved
• These are highly regulated by the FDA, we can't. go back and just take care of these patients.
• This is a FDA Category 3 device, so it's highly rec... highly regulated, the materials that are used,
• They are a class 2 FDA medical. equipment.

Bills: HB2646, HB3941, HB5153, HB5155, HB5394, HB 1106, HB426, HB4529, HB3984, HB4273, HB 1097, HB3940, HB1941, HB4377, HB3153

Keywords: child care, task force, high-quality care, affordability, prekindergarten partnerships, foster care, transitional living, Medicaid reform, youth assistance, independent living, services for youth, employment training, educational support, mental health services, health care, public health, child health program, reimbursement, local health entities, maternal health

Transcript Highlights:

• The FDA redefined a hearing aid in 2022.
• The FDA redefined a hearing aid in 2022. Technical in nature.
• The FDA redefined a hearing aid in 2022, so we feel like that should be something that is in California

Summary: The Senate Committee on Appropriations met to consider a large suspense-file agenda, noting that 122 measures met suspense criteria and that several bills listed in the daily file were postponed to the following week. The Department of Finance did not attend because it had no comments on the bills. After establishing a quorum, the committee proceeded through the agenda, with most authors waiving presentation and public testimony limited to fiscal issues. Most measures were moved to the suspense file without objection after brief or no testimony. A number of bills drew support or opposition from outside groups on fiscal grounds, including SB 951, SB 947, SB 954, SB 1031, SB 1291, and SB 1368. Testimony highlighted concerns such as ongoing state or departmental costs, General Fund impacts, broadband and compliance burdens for small mutual water companies, and implementation costs for education, health, and transportation-related proposals. Supporters of some bills argued they would save money over time, such as SB 1067 on early math remediation and SB 1089 on obesity treatment and CalRx partnerships. The committee also heard an author presentation on SB 1089 by Senator Richardson, who said the bill would reduce CalPERS and broader health costs by expanding access to GLP-1 weight-loss drugs for eligible public employees and directing CalRx to pursue production or acquisition of a GLP-1 medication. No committee questions were raised on that measure, and it too was sent to suspense. The hearing concluded with all items heard being moved to the suspense file and the committee adjourned.

Transcript Highlights:

• I can tell you that the FDA does have enforcement regulation guidelines that have to do with selling
• that is sort of the oversight of the federal government and not the state, I can tell you that the FDA

Summary: The caucus reviewed several bills and Senate or conference committee amendments, with members generally noting whether the sponsor intended to concur. HB 2749 would let courts enter a Class 1 misdemeanor conviction for certain lower-level felony convictions, with the Senate amendment requiring at least five years since completion of sentence before eligibility. HB 2082 would create a childhood cancer and rare childhood disease research commission and adjust funding rules, including a five-million-dollar threshold tied to appropriations or federal grants. HB 2096 would allow counties to seek WIFA assistance for cesspool remediation, with the Senate adding an alternative compliance path using ADEQ’s nonpoint source management plan. HB 4001 would regulate alternative nicotine products through the Department of Liquor Licensing and Control; members discussed whether some tobacco-related products remain outside the bill, tribal enforcement limits, and the absence of a tax provision. The presenter said the AG and governor support the bill. The caucus then shifted to conference committee bills. HB 2003 would lower the learner’s permit age from 15.5 to 15 and increase supervised driving time, but several members raised safety concerns and questioned whether the change was needed; the conference amendment would let current instruction permit holders qualify for a license after six months, while still requiring age 16 for licensure. HB 2133 would impose content-verification requirements for commercial websites publishing sexual material, with conference changes exempting pre-effective-date motion pictures and television programming. Members noted the Motion Picture Association still had concerns, though the changes addressed some retroactivity issues. HB 2874 would change campaign finance penalty rules, including a five-day publication requirement for committees owing late-filing penalties, a $5,000 cap on penalties per late report, and retroactive relief for certain inactive committees that filed no-contribution/no-expenditure reports and later terminated; one member said they still had not received the outstanding fee totals requested on the floor. HB 2010 would regulate digital goods sellers and refunds for revoked access to licensed digital content; the conference version kept a five-year refund structure but changed the refund amount to 20% per year, clarified refund procedures, and removed the refund requirement if alternative access is provided. The caucus took no votes in the transcript and ended after the bill presentations and questions.

Transcript Highlights:

• In the past few years, we got a 483 from the FDA where they cited that we needed to do certain things
• Louis and the state as a whole has a large manufacturing base, and we're actually taking that FDA-approved

Keywords: 959, house, all

Summary: The committee first called the roll, established a quorum, and then heard Senate Bill 1553 from Senator Curtis Gregory. The bill is aimed at national defense and reshoring critical supply chains to the United States, including pharmaceuticals and critical minerals/materials used in defense and manufacturing. Gregory said the Senate had added clarifying language tying eligible materials to federal critical-material and FDA lists. Supporters testified that the bill could help Missouri compete in sectors now dominated by foreign producers, especially China and India, and could strengthen national security by encouraging domestic production of active pharmaceutical ingredients and critical minerals. Witnesses from Jost Chemical, the Missouri Chamber of Commerce, the API Innovation Center, Doe Run, and Associated Industries of Missouri emphasized the difficulty of competing with subsidized foreign supply chains, the importance of transferable tax credits, and Missouri’s existing industrial base. Several witnesses noted that grants would be harder to administer and that federal support or price stability may still be needed for large-scale projects like mines. No one testified in opposition or for informational purposes. The committee then moved into executive session and voted unanimously to pass Senate Bill 1553, with nine ayes and zero nays.

Transcript Highlights:

• In the past few years, we got a 483 from the FDA where they cited that we needed to do certain things
• Louis and the state in whole has a large manufacturing base, and we're actually taking that FDA-approved

Summary: The committee first established a quorum and heard Senate Bill 1553, sponsored by Senator Curtis Gregory, which would provide incentives related to reshoring critical supply chains for pharmaceuticals and critical minerals/materials. Gregory said the bill is aimed at national defense and clarified that the relevant materials would be tied to federal critical-material and FDA lists. Witnesses in support argued that Missouri has an opportunity to expand production of pharmaceuticals and critical minerals, but that foreign competition, especially from China and India, makes domestic production difficult without incentives. Several witnesses emphasized national security concerns, supply-chain vulnerabilities, and the need for state support to help existing Missouri companies expand into these markets. Support testimony came from Jost Chemical, the Missouri Chamber of Commerce and Industry, the API Innovation Center, Doe Run Company, and Associated Industries of Missouri. Testimony highlighted the difficulty of competing with subsidized foreign producers, the long lead times and capital needs for mines and production lines, and the importance of transferable tax credits and possible future federal support. One witness noted that the bill’s grant component may be more limited and would likely be useful for startup, testing, or initial development rather than fully funding a mine. Another witness suggested that tariffs or price floors could also help create a market for domestic production. There was no opposition or informational testimony. After closing the hearing, the committee moved into executive session and voted Senate Bill 1553 do pass by a unanimous 9-0 roll call vote.

Transcript Highlights:

• also, whereas the government was really pushing for a medication that had not been fully vetted and FDA
• approved while denying a medication that hadn't been FDA approved for this purpose but was already FDA
• approved while denying a vetted and FDA approved while denying a medication<01:04:43.920> that
• medication that hadn't been FDA approved medication that hadn't been FDA approved for<01:04:45.599
• for this purpose but was already FDA for this purpose but was already FDA approved.<01:04:49.359

Keywords: 1189, house, all

Transcript Highlights:

• Second, the FDA has consistently affirmed that approved biosimilars meet the same rigorous standards
• Second, the FDA has consistently affirmed that approved biosimilars meet the same rigorous standards
• Second, the FDA has consistently affirmed that approved biosimilars meet the same rigorous standards
• Second, the FDA has consistently affirmed that approved biosimilars meet the same rigorous standards
• Um, either they're new to the market or they lose their FDA approval.

Keywords: 1183, house

Transcript Highlights:

• has access to the data that gets published and presented before national regulatory groups like the FDA
• He's one of the FDA committee members. I don't really know. Wrapping up? Okay, sure.
• He's one of the FDA committee members. I don't really know. Wrapping up? Okay, sure.
• need physician certification of no need physician certification of no alternative<04:05:49.760> FDA
• approved treatments and alternative FDA approved treatments and then<04:05:51.840> only<04:05

Keywords: 1189, house, all

Transcript Highlights:

• And so, because the FDA hasn't approved... That the FDA hasn't approved.
• When the supply is low, the FDA approves compounding pharmacies for GLP-1, and then as soon as...
• I mean, it's hard for me to imagine that an FDA...
• I mean, it's hard for me to imagine that an FDA...
• But an FDA that thinks it's okay some of the time, except when this manufacturer is charging 10 times

Keywords: 1184, house, all

Transcript Highlights:

• The federal FDA right now has the concurrent dosage at about 16 milligrams.
• now has the The federal uh FDA right now has the concurrent<00:18:05.600> dosage<00:18:05.919
• Major medical and regulatory organizations including SAMHSA, FDA, the DEA, and the Federation of State
• regulatory organizations<00:26:18.320> including<00:26:18.799> SAMA,<00:26:19.520> FDA
• ,<00:26:20.320> the organizations including SAMA, FDA, the organizations including SAMA, FDA

Keywords: 958, all

Summary: The subcommittee met on October 14, approved the minutes, and then took up a large group of staff-suggested amendments to multiple regulations. Those staff amendments were approved without objection and were described as technical changes needed to comply with KRS Chapter 13A and other governing law. The committee then moved out of order to consider Kentucky Board of Medical Licensure regulation 2011 KAR 9:270, which governs buprenorphine prescribing and related standards. Board representatives said the regulation has been updated over time since 2015 and that the current amendments are intended to streamline the rule, remove outdated federal references such as the X-waiver, narrow education requirements to addiction-related topics, and create exceptions for settings like emergency rooms and certain pain treatment situations. The agency amendment would also allow buprenorphine monoproduct for up to 30 days when a patient is transitioning from a full opioid agonist, and would add physicians certified in addiction medicine as eligible specialty consultants. Board officials said the regulation was developed through a two-year process with a work group, informal outreach to medical organizations, and multiple comment periods, and they argued the rule is working because overdose deaths have declined and provider numbers have increased. Several witnesses and committee members raised concerns that the regulation remains too restrictive. Senator Rocky Adams noted that major medical organizations had said the proposed language could restrict access and worsen overdose risk, and he questioned whether the committee was being asked to choose between conflicting expert views. Opponents, including a medical student, a recovery advocate, and Dr. Colleen Ryan of the Kentucky Society of Addiction Medicine, argued the rule is outdated, creates unnecessary barriers to buprenorphine treatment, and should be repealed or substantially revised to align with federal guidance and evidence-based care. They said rigid requirements can discourage treatment and that addiction should be treated like other chronic illnesses. No final vote on the medical licensure regulation is reflected in the transcript excerpt, and the discussion ended with the chair preparing to hear from additional opponents.